In our new article series, we introduce the most exciting venture capital firms that are open for LP investments to our family office network. The article belongs to our exclusive single family office guidebook, where we give guidance on the most relevant topics for newly established and already existing family investment vehicles.

In this article, we talked to Seroba Life Sciences, a Dublin-based venture capital fund focused on biotech and medtech ventures. We decided to get in touch with Seroba due to their successful track record and their rather special focus on life science opportunities.


Familyofficehub.io: Briefly describe your focus: in which kind of startups are you investing, where is your geographical focus, what’s your average ticket size?

Seroba: Seroba is an early-stage investor, more European focused though with some exposure to North America. We invest in both biotech and medtech opportunities, starting with a first up to 5MEur ticket, and overall allocating 10MEur or more to each investee. Investment stage would be from pre-clinical and beyond for biotech, and closer to first-in-man and beyond for medtech.

Familyofficehub.io: What are exciting companies in your portfolio – and why?

Seroba: Beyond past successful exits (Apica, Covagen, Precision Biotics, Prexton, Xention, …), our current portfolio comprises exciting companies such as:

  • Atlantic Therapeutics (urinary incontinence, commercial stage)
    • Novel neuro muscular electrical stimulation device (Innovo ®) to treat a range of incontinence in women and men.
    • 47 million sufferers of urinary incontinence in USA, UK, Germany and France, representing a $4.5bn realisable market opportunity.
    • Opportunity to expand market footprint to treat faecal incontinence and sexual health.
  • Endotronix (heart failure monitoring, clinical stage)
    • The Cordella Heart Failure system combines a novel implantable pulmonary artery pressure (PAP) monitor with cloud-based care platform (myCordella) to monitor heart failure (HF) from the home, significantly reducing hospitalisation. Ongoing FDA and CE Mark trials. Close to 6 million Americans live with Heart Failure, 50% will die within 5 years of diagnosis. Over $31Bn was spent on Heart Failure in USA in 2013, set to rise to $70Bn by 2030.
  • Fusion (targeted radiopharmaceuticals, clinical stage)
    • Nasdaq: FUSN, IPOed in 06-2020; targeted oncology play that combines the potent killing effects of a radioactive with targets over-expressed in cancer tissue. Lead product in clinical testing with a robust pipeline/platform. Signed strategic corporate partnership deal with AstraZeneca.
  • Quanta (haemodialysis, commercial stage)
    • Portable haemodialysis system uniquely applicable across all dialysis segments hospital institution clinic selfcare home
    • Advancing American Kidney Health Initiative (AAKHI) launched in July, 2019, opening up the US market
    • 10 Bn$ addressable market
  • PQB (peripheral vascular disease, clinical stage)
    • Company is developing 2 devices to treat long lesions (up to 46cm) in PVD
    • PVD market is worth $7bn 2020). The Detour device converts an open surgical procedure into an endovascular, minimally invasive procedure and thus represents a new $1.3bn market (USA & EU) to treat long lesions or occlusions (>20cm)
  • Shorla (oncology specialty pharma, clinical stage)
    • Specialised on niche, short time-to-market product development opportunities, to build a portfolio of marketed drugs within a few years
  • Storm (RNA epigenetics, pre-clinical stage)
    • Pioneer and most advanced in the field, robust platform generating broad pipeline
    • Oncology focused to start with, but other therapeutic areas are being explored

Familyofficehub.io: Why should a family office invest in Seroba as LP?

Seroba: Drug and medical device industries are probably amongst the most complex and regulated. Only a specialised, experienced VC fund is able to identify the most promising opportunities and help them grow towards an exit, thanks to being immersed in the healthcare ecosystem. Investing into both biotech and medtech allows Seroba to have a holistic view as to what is best to address unmet medical needs. Seroba exploits the great science available in Western Europe, while building bridges with North America for their growth whenever relevant.

Familyofficehub.io: Thanks for your time!


seroba life sciences family office introduction lp
Headquarters: Dublin, Ireland
Website: https://www.seroba-lifesciences.com


In our new article series, we introduce the most exciting venture capital firms that are open for LP investments to our family office network. The article belongs to our exclusive single family office guidebook, where we give guidance on the most relevant topics for newly established and already existing family investment vehicles.

In this article, we talked to Senovo, a Munich-based venture capital fund. We decided to get in touch with Senovo due to their exciting B2B SaaS investment focus.


Familyofficehub.io (FO): Briefly describe your focus: in which kind of startups are you investing, where is your geographical focus, what’s your average ticket size?

Senovo: Senovo is an early-stage venture capital firm based in Munich and Berlin that partners with exceptional founders building global B2B SaaS category-leaders from Europe.

As European first-mover, the fund invests since 2013 into a new generation of B2B software startups which enable the digitalization of medium and large enterprises. Their focus is primarily on supporting teams working in the areas of process optimization, industry 4.0 and data-enabled solutions.

Senovo joins the journey after a company has first revenues in a late Seed or Series A round. Their team of SaaS specialists seek meaningful eye-level relationships and regularly publish their learnings and thought leadership at www.medium.com/senovovc.

FO: What are exciting companies in your portfolio?

Senovo: Among our most successful B2B SaaS companies are: Riskmethods, Anyline, Manta, and Quantilope

FO: Why should a family office invest in Senovo as LP?

Senovo: Europe is the perfect breeding ground for B2B Software Companies. However, specialization is crucial for outstanding returns. Our true edge is (1) a strong market positioning: with 3 previous funds, we are the European expert for early stage B2B SaaS, increasing credibility with founders and high-quality inbound dealflow, (2) we invest in category leaders across Europe – not just the best domestic player and (3) our approach is pandemic/recession proof – 2020 – a strong year for B2B SaaS, our companies remained solid and successful

FO: Thanks for your time!


senovo family office lp investments

Headquarter: Munich, Germany
Website: https://senovo.vc